From the Shiraz Organ Transplant Center, Namazi Teaching Hospital, Shiraz University of Medical Sciences, Shiraz, I. R. Iran.
Exp Clin Transplant. 2020 Feb;18(1):65-70. doi: 10.6002/ect.2017.0110. Epub 2018 Apr 20.
Liver replacement continues to be the only definitive mode of therapy for children with end-stage liver disease. However, it remains challenging because of the rare donor organs, complex surgical demands, and the necessity to prevent long-term complications. Our objectives were to analyze 16 years of experience in the Shiraz University Organ Transplant Center.
We retrospectively analyzed the records of 752 patients (< 18 years old) who underwent orthotopic liver transplant at our center over a 16-year period. Mean age was 90 months, and male-to-female ratio was 1.25. Of the 752 transplants, 354 were whole organs, 311 were from living related donors, and 87 were in situ split liver allografts. Patient and graft survival rates were determined at 1, 3, and 5 years, and results between groups were compared.
Overall mortality was 31.8%. The 1-, 3-, and 5-year patient survival rates were 77%, 69%, and 66%, respectively, whereas the respective graft survival rates were 75%, 68%, and 65%. We observed significant differences in survival according to graft type (log-rank test, P < .001). We also observed significant differences in survival probabilities according to age (log-rank test, P < .001). Cox regression was used to simultaneously analyze effects of age and graft type on survival. Both graft type and age significantly affected survival (P < .001). The 1-, 3, and 5-year survival rates for patients having whole organ transplants were 88%, 81%, and 78%. Patients who received living donor grafts had respective survival rates of 66%, 60%, and 58%, with rates of 65%, 47%, and 47% for patients who received split grafts.
Our results were similar to those observed in the literature in terms of indication for transplant and posttransplant survival.
肝脏替代仍然是治疗终末期肝病儿童的唯一确定性治疗方法。然而,由于供体器官罕见、手术需求复杂以及预防长期并发症的必要性,这仍然具有挑战性。我们的目的是分析 Shiraz 大学器官移植中心 16 年的经验。
我们回顾性分析了 16 年来在我们中心接受原位肝移植的 752 例(<18 岁)患者的记录。平均年龄为 90 个月,男女比例为 1.25。在 752 例移植中,354 例为全器官,311 例来自活体相关供体,87 例为原位劈裂肝同种异体移植。确定了 1、3 和 5 年的患者和移植物存活率,并比较了各组之间的结果。
总体死亡率为 31.8%。1、3 和 5 年的患者生存率分别为 77%、69%和 66%,相应的移植物生存率分别为 75%、68%和 65%。根据移植物类型(对数秩检验,P<.001)观察到生存率存在显著差异。我们还观察到生存率根据年龄(对数秩检验,P<.001)存在显著差异。Cox 回归用于同时分析年龄和移植物类型对生存率的影响。移植物类型和年龄均显著影响生存率(P<.001)。接受全器官移植的患者 1、3 和 5 年的生存率分别为 88%、81%和 78%。接受活体供体移植物的患者的生存率分别为 66%、60%和 58%,接受劈裂移植物的患者的生存率分别为 65%、47%和 47%。
我们的结果与文献中观察到的移植适应证和移植后生存率相似。